EP0636180A1 - T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA) - Google Patents

T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA)

Info

Publication number
EP0636180A1
EP0636180A1 EP93911584A EP93911584A EP0636180A1 EP 0636180 A1 EP0636180 A1 EP 0636180A1 EP 93911584 A EP93911584 A EP 93911584A EP 93911584 A EP93911584 A EP 93911584A EP 0636180 A1 EP0636180 A1 EP 0636180A1
Authority
EP
European Patent Office
Prior art keywords
seq
amb
rae
peptide
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93911584A
Other languages
German (de)
English (en)
French (fr)
Inventor
Mei-Chang Kuo
Richard D. Garman
Julia L. Greenstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immulogic Pharmaceutical Corp
Original Assignee
Immulogic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corp filed Critical Immulogic Pharmaceutical Corp
Priority to EP96202492A priority Critical patent/EP0770681A3/en
Publication of EP0636180A1 publication Critical patent/EP0636180A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • Amb a II (AgK)
  • Amb a I or AgE can be purified using conventional chromatographic or biochemical techniques.
  • ⁇ and ⁇ two noncovalently associated chains of 26 and 12 kD molecular mass
  • I-depleted pollen extract led to the estimation that at least 90% of the allergenic activity in ragweed pollen can be attributed to Amb a I (King, T.P., et al.. Biochemistry. 2:458 (1964); King, T.P., et al.,
  • Amb a I was reported to be a family of homologous, but distinguishable sequences (Rafnar, T., et al., JLs.
  • Amb a I family designated Amb a 1.1, Amb a 1.2, and
  • Amb a I.D (Amb a 1.4) is disclosed in U.S.S.N.
  • the present invention provides isolated peptides of the major protein allergens of Ambrosia artemisiifolia including peptides derived from the family of related proteins, previously designated Amb a, IA, Amb a IB, Amb ' a IC, and Amb a ID. These allergens have been renamed according to the IUIS
  • Peptides within the scope of the invention comprise at least one T cell epitope, preferably at least two T cell epitopes, of a protein allergen selected from the family of Amb a I allergens and Amb a II.
  • the invention further provides peptides comprising at least two regions, each region comprising at least one T cell epitope of a ragweed pollen allergen. The regions are derived from the same or from different ragweed pollen allergens.
  • the invention also provides modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects as well as modified peptides having improved properties such as increased solubility and stability.
  • Peptides of the invention are capable of modifying, in a ragweed pollen-sensitive individual to whom they are administered, the allergic response of the individual to a ragweed pollen allergen. Methods of treatment or of diagnosis of sensitivity to a ragweed pollen allergen in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.
  • Fig. 1 shows Western blot analysis of IgE binding to recombinant Amb a I proteins. - A -
  • Fig. 2 is a graphic representation of a direct binding assay of IgE from a single ragweed allergic patient to recombinant Amb a I and Amb a II proteins.
  • Fig. 3 is a graphic representation of the results of a direct binding assay of IgE from pooled human sera to native Amb a I, Amb a II, recombinant Amb a 1.1, recombinant Amb a II and pollen extract.
  • Fig. 4A and 4B are graphic representations depicting the responses of lymph node cells isolated from mice tolerized in vivo with either Amb a 1.1 or PBS and CFA and challenged in vitro with various antigens.
  • Fig. 5A-5F are graphic representations depicting the responses of lymph node cells isolated from mice tolerized in vivo with Amb a 1.1 or pollen extract, challenged with Amb a 1.1, and tested with various antigens.
  • Fig. 6A-6F are graphic representations depicting the responses of lymph node cells isolated from mice tolerized with pollen extract challenged with pollen extract, and tested with various antigens.
  • Fig. 7 shows various peptides of desired length derived from the Amb a 1.1, Amb a 1.2 and Amb a 1.3 protein allergens.
  • Fig. 8 is a graphic representation depicting the responses of T cell lines from 39 patients primed in vitro to recombinant Amb a 1.1 protein and analyzed for response to various overlapping Amb a 1.1 peptides and selected Amb a 1.2 and Amb a 1.3 peptides by percent of positive responses within the individuals tested, the mean stimulation index of positive responses for the peptide and the ranked sum of peptide responses.
  • Fig. 9 shows selected peptides of desired lengths derived from the Amb a 1.1 protein allergen.
  • Fig. 10 is a graphic representation * depicting the responses of T cell lines from 48
  • Fig. 11 is a graphic representation depicting the responses of T cell lines from 48 patients primed in vitro to recombinant Amb a 1.1 protein and analyzed for response to selected peptides derived from Region 2 of the Amb a 1.1 protein, by percent of positive responses within the individuals tested, the mean stimulation index of positive responses for the peptide and the ranked sum of peptide responses.
  • Fig. 12 is a graphic representation depicting the responses of T cell lines from 48 patients primed in vitro to recombinant Amb a 1.1 protein and analyzed for response to selected peptides derived from Region 3 of the Amb a 1.1 protein, by percent of positive responses within the individuals tested, the mean stimulation index of positive responses for the peptide and the ranked sum of peptide responses.
  • Fig. 13 is a graphic representation
  • Fig. 14 shows selected peptides of desired lengths derived from the Amb a 1.1 protein allergen and the Amb a 1.3 protein allergen.
  • Fig. 15 is a graphic representation depicting the responses of T cell lines from 23 patients primed in vitro to recombinant Amb a 1.1 protein and analyzed for response to selected peptides derived from Region 1 of the Amb a 1.1 protein, by percent of positive responses within the individuals tested, the mean stimulation index of positive responses for the peptide and the ranked sum of peptide responses.
  • Fig. 16 is a graphic representation depicting the responses of T cell lines from 23 patients primed in vitro to recombinant Amb a 1.1 protein and analyzed for response to selected peptides derived from Region 2 of the Amb a 1.1 protein, by percent of positive responses within the individuals tested, the mean stimulation index of positive responses for the peptide and the ranked sum of peptide responses.
  • Fig. 17 is a graphic representation depicting the responses of T cell lines from 23 patients primed in vitro to recombinant Amb a 1.1 protein and analyzed for response to selected peptides derived from Region 3 of the Amb a 1.1 protein, by percent of positive responses within the individuals tested, the mean stimulation index of positive responses for the peptide and the ranked sum of peptide responses.
  • Fig. 18 is a graphic representation depicting the responses of T cell lines from 23 patients primed in vitro to recombinant Amb a 1.1
  • Fig. 19 is a graphic representation depicting the responses of T cell lines of 9 patients primed in vitro to recombinant Amb a 1.1 protein or recombinant Amb a 1.3 protein and analyzed for response to selected peptides derived from Amb a 1.1, by percent of positive responses within the individuals tested and the mean stimulation index of positive responses for the peptide.
  • Fig. 20 is a graphic representation depicting the responses of T cell lines of 9 patients primed in vitro to recombinant Amb a 1.1 protein or recombinant Amb a 1.3 protein and analyzed for response to selected peptides derived from Amb a 1.3, by percent of positive responses within the individuals tested and the mean stimulation index of positive responses for the peptide.
  • Fig. 21 is a graphic representation of a direct binding assay of IgE from a single ragweed allergic patient to peptides derived from Amb a I.
  • Fig. 22 is a graphic representation depicting the responses of T cell lines of 28 ⁇ ⁇ patients primed i vitro to recombinant Amb a 1.1 protein and analyzed for response to selected peptides derived from Amb a I .1 by percent of positive responses within the individuals tested, the mean stimulation index of positive responses to the peptide and the ranked sum of peptide responses.
  • Fig. 23 is a graphic representation depicting the responses of T cell lines of 28 patients primed in vitro to recombinant Amb a 1.1 protein and analyzed for response to selected peptides derived from Region 4 of Amb a 1.1 by percent of positive responses within the individuals tested, the mean stimulation index of positive responses to the peptide and the ranked sum of peptide responses.
  • Fig. 24 is a graphic representation depicting the responses of T cell lines of 32 patients primed in vitro to recombinant Amb a 1.1 protein and analyzed for response to six selected peptides derived from Amb a 1.1 by percent of positive responses within the individuals tested, the mean stimulation index of positive responses to the peptide and the ranked sum of peptide responses.
  • Fig. 25 shows various peptides derived from peptide RAE 70.1 which include modifications designed to increase the solubility of the peptide.
  • Fig. 26 is a graphic representation depicting the response of a T cell line from patient 956.2 primed in vitro to Fel d I and analyzed for response to various peptides derived from the Amb a 1.1 protein.
  • Fig. 27 is a graphic representation depicting the response of a T cell line from patient 119 primed in vitro with recombinant Amb a 1.1 and analyzed for response to various modified peptides derived from Region 2 of the Amb a 1.1 protein by tritiated thy idine incorporation.
  • Fig. 28 is a graphic representation depicting the response of a T cell line from patient 1199 primed in vitro with recombinant Amb a 1.1 and • * analyzed for response to various modified peptides derived from Region 2 of the Amb a 1.1 protein by * tritiated thymidine incorporation.
  • Fig. 29 is a graphic representation depicting the response of a T cell clone generated by limiting, dilution from an Amb a 1.1 specific T cell line stimulated with the AMB 2-10.1 peptide, primed in vitro w/recombinant Amb a 1.1 and analyzed for response to various modified peptides derived from Region 2 of the Amb a 1.1 protein by tritiated thymidine incorporation.
  • Fig. 30 is a graphic representation depicting the percent of total histamine release in blood samples from 8 ragweed-allergic patients in response to selected peptides derived from the Amb a 1.1 protein.
  • the present invention provides isolated peptides derived from the major protein allergens of Ambrosia artemisiifolia.
  • a peptide refers to an amino acid sequence having fewer amino acids than the entire amino acid sequence of a protein from which the peptide is derived.
  • Peptides of the invention include peptides derived from Amb a 1.1, Amb a 1.2, Amb a 1.3, Amb a 1.4 and Amb a II which comprise at least one T cell epitope of the allergen.
  • Peptides comprising at least two regions, each region comprising at least one T cell epitope of a protein allergen of Ambrosia artemisiifolia are also within the scope of the invention. Each region of such peptides is derived from the same or from different ragweed pollen allergens. Isolated peptides or regions of isolated peptides, each comprising at least two T cell epitopes of a ragweed pollen allergen are particularly desirable for increased therapeutic effectiveness. Peptides which are immunologically related (e.g., by antibody or T cell cross-reactivity) to peptides of the present invention are also within the scope of the invention.
  • Peptides immunologically related by antibody cross-reactivity are bound by antibodies specific for a peptide of a protein allergen of Ambrosia ar emisiifolia.
  • Peptides immunologically related by T cell cross-reactivity are capable of reacting with the same T cells as a peptide of the invention.
  • the present invention also pertains to a ragweed pollen allergen encoded by a nucleic acid sequence of clone IPC1/5.
  • the full-length nucleic acid sequence of clone IPC1/5 has been determined and the encoded protein has been produced recombinantly in both the pSEM vector (as a fusion protein with ⁇ -galactosidase) and the pETlld vector.
  • the recombinant protein was determined to bind approximately 10-20% of allergic serum IgE on a Western blot.
  • the protein encoded by clone IPC1/5 was found to have a high degree of amino acid sequence homology with cysteine proteinase inhibitors in man and rice.
  • the protein has 66.6% homology with the rice protein oryzacystatin-I.
  • the nucleic acid sequence and deduced amino acid sequence of the allergen encoded by clone IPC1/5 is represented in SEQ ID NO. 11 and 12.
  • Isolated proteins and isolated peptides of the invention can be produced by recombinant DNA techniques in a host cell transformed with a nucleic acid having a sequence encoding such protein or peptide.
  • the isolated proteins and isolated peptides of the invention can also be produced by chemical synthesis. In certain limited situations, isolated peptides can be produced by chemical cleavage of a protein allergen.
  • host cells transformed with a nucleic acid having a sequence encoding the protein or peptide or the functional equivalent of the nucleic acid sequence are cultured in a medium suitable for the cells and protein or peptides can be purified from cell culture medium, host cells, or both using techniques known in the art for purifying proteins and peptides including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis or immunopurification with antibodies specific for the protein or peptide, the protein allergen of Ambrosia artemisiifolia from which the peptide is derived, or a portion thereof.
  • protein and peptides of the present invention are substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or substantially free of chemical precursors or other chemicals when synthesized chemically.
  • Recombinant ragweed pollen proteins including recombinant Amb a 1.1, Amb a 1.2, Amb a 1.3, Amb a 1.4, and Amb a II have been produced.
  • Suitable expression vectors for producing recombinant protein and recombinant peptides of the invention include pTRC, pGEX, pMAL, pRIT5, pETlld and pCA.
  • the use of pTRC, pETlld and pGEX as expression vectors will result in expression of ragweed pollen protein as an unfused protein.
  • the use of pMAL, pRIT5, pCA and pSEM as expression vectors will result in expression of ragweed pollen protein fused to maltose E binding protein (pMAL) , protein A (pRIT5), truncated protein A (pCA), or ⁇ -galactosidase (pSEM) .
  • Suitable expression vectors are commercially available. When produced as a fusion protein, recombinant ragweed pollen protein can be recovered from the fusion protein through enzymatic or chemical (e.g., cyanogen bromide or dilute acid) cleavage and biochemical purification. For example, enzymatic cleavage sites for Factor X or thrombin can be introduced at the fusion junction between the carrier protein (e.g., Protein A) and the ragweed pollen protein.
  • Suitable host cells for expression of recombinant ragweed pollen protein include bacteria, yeast and insect or mammalian cells. Appropriate vectors for expression in yeast include YepSec, pMF ⁇ and JRY88. These vectors are also commercially available.
  • a ragweed pollen allergen is divided into non-overlapping peptides of desired lengths or overlapping peptides of desired lengths as discussed in Example V which may be produced recombinantly, synthetically or in certain limited situations by chemical cleavage of the allergen.
  • Peptides comprising at least one T cell epitope are capable of eliciting a T cell response, such as T cell proliferation or lymphokine secretion and/or are capable of inducing T cell anergy (i.e., tolerization) .
  • isolated peptides are tested by, for example, T cell biology techniques to determine whether the peptides elicit a T cell response or induce T cell anergy. Those peptides found to elicit a T cell response or induce T cell
  • anergy are defined as having T cell stimulating activity.
  • human T cell stimulating activity can be tested by culturing T cells obtained from an individual sensitive to a ragweed pollen allergen, (i.e., an individual who has an IgE mediated immune response to a ragweed pollen allergen) with a peptide derived from the allergen and determining whether proliferation of T cells occurs in response to the peptide as measured, e.g., by cellular uptake of tritiated thymidine.
  • stimulation indices for responses by T cells to peptides can be calculated as the maximum CPM in response to a peptide divided by the medium control CPM.
  • a peptide comprising at least one T cell epitope when determined by T cell stimulation requires a stimulation index of at least 2.0.
  • a peptide having a T cell stimulation index of 2.0 is considered useful as a therapeutic agent.
  • Preferred peptides have a stimulation index of at least 2.5, more preferably at least 3.5, and most preferably at least 5.0.
  • a peptide having T cell stimulating activity and thus comprising at least one T cell epitope as determined by T cell biology techniques is modified by addition or deletion of amino acid residues at either the amino or carboxy terminus of the peptide and tested to determine a change in T cell reactivity to the modified peptide. If two or more peptides which share an area of overlap in the native protein sequence are found to have human T cell stimulating activity, as determined by T cell biology techniques, additional peptides can be produced comprising all or a portion of such peptides and these additional peptides can be tested by a similar procedure. Following this technique, peptides are selected and produced recombinantly or synthetically.
  • Peptides are selected based on various factors, including the strength of the T cell response to the peptide (e.g., stimulation index), the frequency of the T cell response to the peptide in a population of individuals sensitive to ragweed pollen, and the potential cross-reactivity of the peptide with Amb a I family members and Amb a II.
  • the physical and chemical properties of these selected peptides e.g., solubility, stability
  • the ability of the selected peptides or selected modified peptides to stimulate human T cells e.g., induce proliferation, lymphokine secretion is determined.
  • preferred peptides of the invention do not bind immunoglobulin E (IgE) or bind IgE to a substantially lesser extent than the protein allergen from which the peptide is derived binds IgE.
  • Recombinant ragweed pollen allergens including recombinant Amb a 1.1, Amb a 1.2, Amb a 1.3, Amb a 1.4, and Amb a II have been produced and shown to have reduced IgE binding activity as compared to the corresponding native protein allergen (See Fig. 3).
  • the major complications of standard immunotherapy are IgE-mediated responses such as anaphylaxis.
  • Immunoglobulin E is a mediator of anaphylactic reactions which result from the binding and cross-linking of antigen to IgE on mast cells or basophils and the release of mediators (e.g., histamine, serotonin, eosinophil chemotacic factors).
  • mediators e.g., histamine, serotonin, eosinophil chemotacic factors.
  • anaphylaxis in a substantial percentage of a population of individuals sensitive to ragweed pollen allergen could be avoided by the use in immunotherapy of a recombinant protein, a peptide or peptides which do not bind IgE in a substantial percentage (e.g., at least about 75%) of a population of individuals sensitive to ragweed pollen allergen, or if the protein or peptide(s) binds IgE, such binding does not result in the release of mediators from mast cells or basophils.
  • the risk of anaphylaxis can be reduced by the use in immunotherapy of a recombinant protein, a peptide or peptides which have reduced IgE binding.
  • Minimal IgE stimulating activity refers to IgE production that is less than the amount of IgE production and/or IL-4 production stimulated by the native protein allergen (e.g. , Amb a 1.1) .
  • a peptide or recombinant protein of the invention when administered to a ragweed pollen-sensitive individual, is capable of modifying the allergic response of the individual to the allergen.
  • peptides of the invention comprising at least one T cell epitope of a ragweed pollen allergen or at least two regions derived from a ragweed pollen allergen each comprising at least one T cell epitope, when administered to a ragweed pollen-sensitive individual are capable of modifying the T cell response of the individual to the allergen.
  • modification of the allergic response of a ragweed pollen-sensitive individual to a ragweed pollen allergen can be defined as non-responsiveness or diminution in symptoms to a ragweed pollen allergen, as determined by standard clinical procedures (see e.g., Varney et al., British Medical Journal 302: 265-269 (1990)).
  • T cell epitopes are believed to be involved in initiation .and perpetuation of the immune response to ragweed pollen allergen(s) which are responsible for the clinical symptoms of ragweed pollen allergy.
  • These T cell epitopes are thought to trigger early events at the level of the T helper cell by binding to an appropriate HLA molecule on the surface of an antigen presenting cell and stimulating the relevant T cell subpopulation. These events lead to T cell proliferation, lymphokine secretion, local inflammatory reactions, the recruitment of additional immune cells to the site, and activation of the B cell cascade leading to production of antibodies.
  • T cell epitope is the basic element or smallest unit of recognition by a T cell receptor, where the epitope comprises amino acid residues essential to receptor recognition which may be contiguous and/or non-contiguous in the amino acid sequence of the protein.
  • Amino acid sequences which mimic those of T cell epitopes and which modify the allergic response to protein allergens of Ambrosia artemisiifolia are within the scope of this invention.
  • Exposure of ragweed pollen allergic patients to peptides of the present invention may tolerize or anergize appropriate T cell subpopulations such that they become unresponsive to ragweed pollen allergen(s) and do not participate in mounting an immune response upon such exposure.
  • administration of a peptide of the present invention may modify the lymphokine secretion profile as compared with exposure to the naturally-occurring ragweed pollen allergen or portion thereof (e.g., result in a decrease of IL-4 and/or an increase in IL-2) .
  • T cell subpopulations which normally participate in the response to ragweed pollen allergen(s) such that these T cells are drawn away from the site(s) of normal exposure to the allergen (e.g., nasal mucosa, skin, and lung) towards the site(s) of therapeutic administration of the peptide.
  • This redistribution of T cell subpopulations may ameliorate or reduce the ability of an individual's immune system to stimulate the immune response at the site of normal exposure to the ragweed pollen allergen(s), resulting in a diminution in allergic symptoms.
  • Isolated peptides of the invention comprise at least one T cell epitope of a protein allergen of Ambrosia artemisiifolia (i.e., the peptide comprises at least approximately seven amino acid residues of the protein allergen) .
  • therapeutic compositions of the invention preferably comprise at least two T cell epitopes of a ragweed pollen allergen.
  • isolated peptides of the invention preferably comprise at least two T cell epitopes (i.e., the peptide comprises at least approximately eight amino acid residues, and preferably fifteen amino acid residues) .
  • isolated peptides of the invention preferably comprise a sufficient percentage of the T cell epitopes of the entire protein allergen such that upon administration of the peptide to an individual sensitive to ragweed pollen, T cells of individual are tolerized to the protein allergen.
  • Isolated peptides of the invention comprising up to approximately 45 amino acid residues in length, and most preferably up to approximately 30 amino acid residues in length are particularly desirable as increases in length may result in difficulty in peptide synthesis as well as retention of an undesirable property (e.g., immunoglobulin binding or enzymatic activity) due to maintenance of conformational similarity between the peptide and the protein allergen from which it is derived. All of the peptides shown in Fig. 8 were found to have human T cell stimulating activity.
  • Preferred peptides comprise all or a portion of the areas of major T cell reactivity within the Amb a 1.1 protein allergen, i.e., Region 1, Region 2, Region 3 and Region 4. Each area is broadly defined as follows: Region 1 comprises amino acid residues 48-107; Region 2 comprises amino acid residues 171-216; Region 3 comprises amino acid residues 278-322; and Region 4 comprises amino acid residues 331-377. Preferred areas of major T cell reactivity within each Region comprise: amino acid residues 57-101; amino acid residues 182-216; amino acid residues 280-322; and amino acid residues 342-377.
  • Amb a 1.1 stimulated T cells have been shown to recognize both Amb a 1.1 derived peptides and homologous Amb a 1.3 derived peptides (See Example IX) .
  • Amb a 1.3 stimulated T cell recognize both Amb a 1.1 and Amb a 1.3 derived peptides.
  • Preferred ragweed pollen peptides comprise all or a portion of the following peptides: RAE 67.1 (SEQ ID NO:13); RAE 57.1 (SEQ ID NO:14); RAE 24.E (SEQ ID NO:15); RAE 24.1 (SEQ ID NO:16); RAE 22.E (SEQ ID NO:17); RAE 22.E-1 (SEQ ID NO: 18); RAE 3.D (SEQ ID NO:19); RAE 3.1 (SEQ ID NO:20); RAE 22.E-2 (SEQ ID NO:21); RAE 5.D (SEQ ID NO:22); RAE 6.D (SEQ ID NO:23); RAE 6.1 (SEQ ID NO:24); RAE 7.D (SEQ ID NO:13); RAE 57.1 (SEQ ID NO:14); RAE 24.E (SEQ ID NO:15); RAE 24.1 (SEQ ID NO:16); RAE 22.E (SEQ ID NO:17); RAE 22.E-1 (SEQ ID NO: 18); RAE 3.
  • RAE 7.D-1 (SEQ ID NO:26); RAE 40.1-6 (SEQ ID NO:27) RAE 40.1-5 (SEQ ID NO:28); RAE 40.1-4 (SEQ ID NO:29) RAE 40.D (SEQ ID NO:30); RAE 40.1 (SEQ ID NO:31) RAE 61.1 (SEQ ID NO:32); RAE 80.1 (SEQ ID NO:33) RAE 45.1 (SEQ ID NO:34); RAE 75.1 (SEQ ID NO:35) RAE 62.1 (SEQ ID NO:36); RAE 69.1 (SEQ ID 69.1-1 (SEQ ID NO: 38); RAE 69.1-2 (SEQ ID 69.1-3 (SEQ ID NO:40); RAE 70.1-3 (SEQ ID 70.1-2 (SEQ ID NO: 42); RAE 70.1-1 (SEQ ID 70.1 (SEQ ID NO: 44); RAE 71.1 (SEQ ID 65.1 (SEQ ID NO:46); RAE 63.1 (SEQ ID 76.1 (SEQ ID NO
  • SEQ ID NO: 70 RAE 20.1 (SEQ ID 20.1-3 (SEQ ID NO: 72); RAE 20.1-2 (SEQ ID 20.1-1 (SEQ ID NO: 74); RAE 21.1 (SEQ ID 17.1 (SEQ ID NO:76); RAE 55.1 (SEQ ID 76.6 (SEQ ID NO: 78); RAE 67.15 (SEQ ID 45.15 (SEQ ID NO: 80); RAE 27.15 (SEQ ID 1-1.1 (SEQ ID NO: 85) AMB 1-2.1 (SEQ ID 1-3.1 (SEQ ID NO: 87) AMB 1-4.1 (SEQ ID 1-5.1 (SEQ ID NO: 83) AMB 1-6.1 (SEQ ID NO: 70); RAE 20.1 (SEQ ID 20.1-3 (SEQ ID NO: 72); RAE 20.1-2 (SEQ ID 20.1-1 (SEQ ID NO: 74); RAE 21.1 (SEQ ID 17.1 (SEQ ID NO:76); RAE 55.1 (SEQ ID 76.6 (SEQ ID NO: 78); RAE 67
  • Particularly preferred peptides comprise all or a portion of the following peptides: AMB 1-2.1 (SEQ ID NO:86); AMB 2-6.1 (SEQ ID NO:93); AMB 2-4.1 (SEQ ID NO:90); Amb 2-36.1 (SEQ ID NO:139); Amb 2-38.1 (SEQ ID NO:141); RA-02.1 (SEQ ID NO:150); AMB 2-9.1 (SEQ ID NO:98); AMB 3-5.1 (SEQ ID NO:102); and AMB 4-9.1 (SEQ ID NO:110).
  • Another embodiment of the present invention provides peptides comprising at least two regions, each region comprising at least one T cell epitope of a protein allergen of Ambrosia artemisiifolia (e.g., each region comprises at least approximately seven amino acid residues) .
  • These peptides comprising at least two regions can comprise as many amino acid residues as desired and preferably comprise at least about 7, more preferably at least about 15, even more preferably about 30 and most preferably at least about 40 amino acid residues of a ragweed pollen allergen.
  • Each region of such peptide preferably comprises up to 45 amino acid residues in length, more preferably up to 40 residues in length and most preferably up to 30 amino acid residues in length as increases in length of a region may result in difficulty in peptide synthesis as well as retention of an undesirable property (e.g., immunoglobulin binding or enzymatic activity) due to maintenance of conformational similarity between the peptide and the protein allergen from which it is derived.
  • the amino acid sequences of the regions can be produced and joined by a linker to increase sensitivity to processing by antigen-presenting cells.
  • linker can be any non-epitope amino acid sequence or other appropriate linking or joining agent.
  • the regions are arranged in a configuration different from a naturally-occurring configuration of the regions in the allergen.
  • the regions containing T cell epitope(s) can be arranged in a noncontiguous configuration and can preferably be derived from the same protein allergen.
  • Noncontiguous is defined as an arrangement of regions containing T cell epitope(s) which is different than that of an amino acid sequence present in the protein allergen from which the regions are derived.
  • noncontiguous ' regions containing T cell epitopes can be arranged in a nonsequential order (e.g., in an order different from the order of the amino acids of the native protein allergen from which the region containing T cell epitope(s) are derived in which amino acids are arranged from an amino terminus to a carboxy terminus) .
  • a peptide can comprise at least 15%, at least 30%, at least 50% or up to 100% of the T cell epitopes of a ragweed pollen allergen.
  • the individual peptide regions can be produced and tested to determine which regions bind immunoglobulin E specific for a ragweed pollen allergen and which of such regions would cause the release of mediators (e.g., histamine) from mast cells or basophils.
  • mediators e.g., histamine
  • Those peptide regions found to bind immunoglobulin E and cause the release of mediators from mast cells or basophils in greater than approximately 10-15% of the allergic sera tested are preferably not included in the peptide regions arranged to form peptides of the invention.
  • Preferred peptides of the invention comprise two or more regions derived from the same or from different' ragweed pollen allergens (e.g., Amb a I.l, Amb a 1.2, Amb a 1.3, Amb a • I.4 and Amb a II).
  • one region can be derived from Amb a I.l and one region can be derived from Amb a 1.2; one region can be derived from Amb a I.l and one region can be derived from Amb a 1.3; one region can be derived from Amb a I.l and one region can be derived from Amb a .
  • one region can be derived from Amb a 1.2 and one region can be derived from Amb a 1.3; one region can be derived from Amb a 1.2 and one region can be derived from Amb a 1.4; one region can be derived from Amb a 1.3 and one region can be derived from Amb a 1.4; one region can be derived from Amb a I.l and one region can be derived from Amb a II; one region can be derived from Amb a 1.2 and one region can be derived from Amb a II; one region can be derived from Amb a 1.3 and one region can be derived from Amb a II; and one region can be derived from Amb ⁇ . 1.4 and one region can be derived from Amb a II.
  • the regions can be derived from the same protein allergen, e.g., Amb a I.l and Amb a I.l, etc.
  • Regions of a peptide of the invention preferably comprise all or a portion of Region 1, Region 2, Region 3 and Region 4 of Amb a I.l, and the above discussed preferred areas of major T cell reactivity within each Region. If Region 1, 2, 3 or 4 is found to bind IgE and cause the release of mediators from mast cells or basophils, then it is preferred that more than one region of the peptide comprise such Region and that the various regions of the peptide do not bind IgE or cause release of mediators from mast cells or basophils.
  • Examples of preferred regions include: AMB 1-1.1 (SEQ ID NO:85); AMB 1-2.1 (SEQ ID NO:86); AMB 1-3.1 (SEQ ID NO:87); AMB 1-4.1 (SEQ ID NO:84); AMB 1-5.1 (SEQ ID NO :83); AMB 1-6.1 (SEQ ID NO:82); AMB 1-4.15 (SEQ ID NO:88); AMB 1-2.15 (SEQ ID NO:89); AMB 2-4.1 (SEQ ID NO:90); AMB 2-3.1 (SEQ ID N0:91); AMB 2-5.1 (SEQ ID NO:92); AMB 2-6.1 (SEQ ID NO:93); AMB 2-2.1 (SEQ ID NO: 94); AMB 2-1.1 (SEQ ID NO:95); AMB 2-7.1 (SEQ ID NO:96); AMB 2-8.1 (SEQ ID NO:97); AMB 2-9.1 (SEQ ID NO: 98); AMB 2-10.1 (SEQ ID NO: 99); AMB 2-11.1 (SEQ ID NO: 100); AMB 2-1.15 (SEQ
  • Preferred peptides comprise various combinations of two or more regions, each region comprising all or a portion of Region 1, Region 2, Region 3 or Region 4 of Amb a I.l.
  • Preferred peptides comprise various combinations of two or more regions, each region having an amino acid sequence as shown in Fig. 14, such combination of regions including the following: AMB 4-6.1 and RAE 70.1 (SEQ ID NO:111 and SEQ ID NO:44); AMB 4-6.1 and AMB 2-5.1 (SEQ ID NO:111 and SEQ ID NO:92); AMB 4-9.1 and AMB 2-5.1 (SEQ ID NO:110 and SEQ ID NO:92); AMB 4-9.1 and RAE 70.1 (SEQ.
  • AMB 4-6.1, AMB 2-5.1 and AMB 1-2.1 (SEQ ID NO:111, SEQ ID NO:92 and SEQ ID NO:86); AMB 4-9.1, AMB 2-5.1 and AMB 1-2.1 (SEQ ID NO:110, SEQ ID NO:92 and SEQ ID NO:86); AMB 4-6.1, RAE 70.1 and AMB 1-2.1 (SEQ ID NO:111, SEQ ID NO:44 and SEQ ID NO:86); AMB 4-9.1, RAE 70.1 and AMB 1-2.1 (SEQ ID NO:110, SEQ ID NO:44 and SEQ ID NO:86); AMB 4-6.1, RAE 70.1, AMB 1-2.1 and AMB 3-5.1 (SEQ ID NO:111, SEQ ID NO:44, SEQ ID NO:86 and SEQ ID NO: 102); AMB 4-9.1, RAE 70.1, AMB 1-2.1 and AMB 3-5.1 (SEQ ID NO:110, SEQ ID NO:44, SEQ ID NO:86 and SEQ ID NO:102); AMB 4-9.1, RAE 70.1, AMB 1-
  • Peptides of protein allergens of Ambrosia artemisiifolia within the scope of the invention can be used in methods of treating and preventing allergic reactions to ragweed pollen allergens.
  • one aspect of the present invention provides therapeutic compositions comprising a peptide of Amb a. I.l, Amb a 1.2, Amb a 1.3, Amb a 1.4 or Amb a II including at least one T cell epitope, or preferably at least two T cell epitopes, and a pharmaceutically acceptable carrier or diluent.
  • the therapeutic composition comprises a pharmaceutically acceptable carrier or diluent and a peptide comprising at least two regions, each region comprising at least one T cell epitope of a ragweed pollen allergen and is derived from the same or from different ragweed pollen allergens.
  • a peptide derived from a ragweed pollen allergen comprising at least one T cell epitope can be administered in combination with an appropriate diluent, a carrier, and/or an adjuvant.
  • peptides are administered in soluble form.
  • Pharmaceutically acceptable diluents include saline and aqueous buffer solutions.
  • Pharmaceutically acceptable carriers include polyethylene glycol (Wie et al., International Archives of Allergy and Applied Immunology 64: 84-99 (1981)) and liposomes (Strejan et al..
  • compositions are preferably administered in non-immunogenic form, e.g., one that does not include adjuvant.
  • Such compositions will generally be administered by injection (e.g., intravenous, subcutaneous, intramuscular), oral administration, (e.g., as in the form of a capsule), inhalation, transdermal application or rectal administration.
  • therapeutic compositions are administed subcutaneously.
  • the therapeutic compositions of the invention are administered to ragweed pollen-sensitive individuals at dosages and for lengths of time effective to reduce sensitivity (i.e., reduce the allergic response) or tolerize an individual to a ragweed pollen allergen.
  • a therapeutically effective amount of one or more of the same or of different therapeutic compositions can be administered simultaneously or sequentially to a ragweed pollen-sensitive individual. Effective amounts of the therapeutic compositions will vary according to factors such as the degree of sensitivity of the individual to ragweed pollen allergens, the age, sex, and weight of the individual, and the ability of the peptide to stimulate a T cell response in the individual.
  • compositions comprising at least two peptides (e.g., a physical mixture of at least two peptides), each comprising at least one T cell epitope of a protein allergen of Ambrosia artemisiifolia.
  • Compositions comprising several peptides or combinations of separate peptides can include as many peptides as desired (e.g., 5, 6, 7...) for therapeutic efficacy.
  • the peptides are derived from the same or from different ragweed pollen allergens.
  • Such compositions can be administered in the form of a therapeutic composition with a pharmaceutically acceptable carrier or diluent.
  • peptides are administered in soluble form.
  • a therapeutically effective amount of one or more of such compositions can be administered simultaneously or sequentially, preferably subcutaneously, to a ragweed pollen-sensitive individual to desensitize or tolerize the individual to ragweed pollen.
  • compositions and preferred combinations of peptides which can be administered simultaneously or sequentially include the following combinations: AMB 4-6.1 and RAE 70.1 (SEQ ID NO:111 " and SEQ ID NO:44); AMB 4-6.1 and AMB 2-5.1 (SEQ ID NO:111 and SEQ ID NO:92); AMB 4-9.1 and AMB 2-5.1 (SEQ ID NO:110 and SEQ ID NO:92); AMB 4-9.1 and RAE 70.1 (SEQ.
  • AMB 4-6.1, AMB 2-5.1 and AMB 1-2.1 (SEQ ID NO:lll, SEQ ID NO:92 and SEQ ID NO: 86); AMB 4-9.1, AMB 2-5.1 and AMB 1-2.1 (SEQ ID NO:110, SEQ ID NO:92 and SEQ ID NO:86); AMB 4-6.1, RAE 70.1 and AMB 1-2.1 (SEQ ID NO:lll, SEQ ID NO:44 and SEQ ID NO:86); AMB 4-9.1, RAE 70.1 and AMB 1-2.1 (SEQ ID NO:110, SEQ ID NO:44 and SEQ ID NO:86); AMB 4-6.1, RAE 70.1, AMB 1-2.1 and AMB 3-5.1 (SEQ ID NO:111, SEQ ID NO:44, SEQ ID NO:86 and SEQ ID NO:102); AMB 4-9.1, RAE 70.1, AMB 1-2.1 and AMB 3-5.1 (SEQ ID NO:110, SEQ ID NO:44, SEQ ID NO:86 and SEQ ID NO:102);
  • compositions and preferred combinations of peptides for therapeutic administration include the following combinations: AMB 1-2.1 and AMB 4-9.1 (SEQ ID NO: 86 and SEQ ID NO:110); AMB 1-2.1, Amb 2-38.1 and AMB 4-9.1 (SEQ ID NO:86, SEQ ID NO:141 and SEQ ID NO:110); AMB 1-2.1, Amb 2-38.1, AMB 4-9.1 and AMB 2-4.1 (SEQ ID NO:86, SEQ ID NO:141, SEQ ID NO:110 and SEQ ID NO:90); AMB 1-2.1, Amb 2-38.1, AMB 4-9.1, AMB 2-4.1 and AMB 3-5.1 (SEQ ID NO:86, SEQ ID N0:141, SEQ ID NO:110, SEQ ID NO:90, and SEQ ID NO:102); AMB 1-2.1, Amb 2-36.1 and AMB 4-9.1 (SEQ ID NO:86, SEQ ID NO:139 and SEQ ID NO:110); AMB 1-2.1, Amb 2-36.1, AMB 4-9.1 and AMB 2-4.1 (SEQ ID NO
  • the present invention also provides methods of detecting sensitivity in individuals to ragweed pollen allergens comprising combining a blood sample obtained from the individual with a peptide of the present invention, under conditions appropriate for binding of blood components with the peptide and determining the extent to which such binding occurs.
  • the extent to which binding occurs is determined by assessing T cell function, T cell proliferation or a combination thereof.
  • a modified peptide can be produced in which the amino acid sequence has been altered, such as by amino acid substitution, deletion, or addition, to modify immunogenicity and/or reduce allergenicity, or to which a component has been added for the same purpose.
  • a peptide can be modified so that it maintains the ability to induce T cell anergy and bind MHC proteins without the ability to induce a strong proliferative response or possibly, any proliferative response when administered in immunogenic form.
  • critical binding residues for the T cell receptor can be determined using known techniques (e.g., substitution of each residue such as, for example, with alanine and determination of the presence or absence of T cell reactivity) .
  • Those residues shown to be essential to interact with the T cell receptor can be modified by replacing the essential amino acid with another, preferably similar amino acid residue (a conservative substitution) whose presence is shown to enhance, diminish, but not eliminate, or not affect T cell reactivity.
  • those amino acid residues which are not essential for T cell receptor interaction can be modified by being replaced by another amino acid whose incorporation may enhance, diminish or not affect T cell reactivity, but riot eliminate binding to relevant MHC.
  • Preferred amino acid substitutions for non-essential amino acids include, but are not limited to substitutions with alanine, gluatamic acid or a methyl amino acid.
  • peptide AMB 4-9.1 which contains an acid-sensitive aspartic acid-proline bond at amino acid residues 360-361, was modified to increase the stability of this peptide.
  • the proline at position 361 was substituted with alanine to remove the acid-sensitive bond.
  • peptides can also be modified to incorporate one or more polymorphisms in the amino acid sequence of a protein allergen resulting from natural allelic variation.
  • D-amino acids, non-natural amino acids or non-amino acid analogues can be substituted or added to produce a modified peptide within the scope of this invention.
  • peptides can be modified using the polyethylene glycol (PEG) method of A. Sehon and co-workers (Wie et al., supra) to produce a peptide conjugated with PEG.
  • PEG polyethylene glycol
  • Modifications of peptides or portions thereof can also include reduction/alkylation (Tarr in: Methods of Protein Microcharacterization. J.E. Silver ed. Humana Press, Clifton, NJ, pp. 155-194 (1986)); acylation (Tarr, supra) ; esterification (Tarr, supra) ; chemical coupling to an appropriate carrier (Mishell and Shiigi, eds. Selected Methods in Cellular Immunology. WH Freeman, San Francisco, CA (1980); U.S. Patent 4,939,239); or mild formalin treatment (Marsh International Archives of Allergy and Applied Immunology 41: 199-215 (1971)).
  • peptides within an allergen group can be modified to enhance T cell reactivity.
  • an allergen group e.g., Amb a I or Amb a II
  • a peptide of one group allergen which may be less reactive than a peptide of another group allergen corresponding in amino acid position can have one or more amino acids substituted with one or more amino acids from the corresponding peptide.
  • peptides can be modified to incorporate a polymorphism in the amino acid sequence of a protein allergen resulting from natural allelic variation. Modification of peptides to include one or more of these polymorphisms may result in enhanced stability and/or reactivity.
  • reporter group(s) to the peptide backbone.
  • poly-histidine can be added to a peptide to purify the peptide on immobilized metal ion affinity chromatography (Hochuli, E. et al., Bio/Technoloov. .6:1321-1325 (1988)).
  • specific endoprotease cleavage sites can be introduced, if desired, between a reporter group and amino acid sequences of a peptide to facilitate isolation of peptides free of irrelevant sequences.
  • a selected peptide AMB 3-4.1 was modified to increase its solubility by the addition of three naturally occurring sequential residues found in the Amb a I.l protein, "RHG", to the 5' end of the peptide. These residues are not necessary for T cell recognition and are also found in peptide AMB 3-5.1.
  • peptide RAE 70.1 was divided into two fragments and modified to increase solubility.
  • a fragment of RAE 70.1 (“ORIGINAL" in Figure 25, amino acid residues 194-216, SEQ ID NO:125) was modified by substitution or addition of amino acids to increase the hydrophilicity and decrease the pi of the peptide to thereby increase the solubility.
  • isoleucine was substituted with glutamic acid to decrease the pi and avoid precipitation of the peptide from solution at a physiological pH. Similar substitutions and additions are shown in Figure 25.
  • canonical protease sensitive sites can be recombinantly or synthetically engineered between regions, each comprising at least one T cell epitope.
  • charged amino acid pairs such as KK or RR, can be introduced within a peptide or at the ends of a peptide during recombinant or synthetic construction of the peptide.
  • the resulting peptide can be rendered sensitive to cathepsin and/or other trypsin-like enzymes cleavage to generate portions of the peptide containing one or more T cell epitopes.
  • such charged amino acid residues can result in an increase in solubility of a peptide.
  • Site-directed mutagenesis of DNA encoding a peptide of the invention can be used to modify the structure of the peptide. Such methods may involve PCR with degenerate oligonucleotides (Ho et al., Gene. .77:51-59 (1989)) or total synthesis of mutated genes (Hostomsky, Z., et al., Biochem. Biophvs. Res. Comm.. 161:1056-1063 (1989)). To enhance bacterial expression, the aforementioned methods can be used in conjunction with other procedures to change the eucaryotic codons in DNA constructs encoding peptides of the invention to ones preferentially used in E. coli. yeast, mammalian cells or other eucaryotic cells.
  • the present invention also provides nucleic acids having sequences encoding proteins and peptides of the invention.
  • Nucleic acid sequences used in any embodiment of this invention can be cDNA as described herein, or alternatively, can be any oligodeoxynucleotide sequence having all or a portion of a sequence represented herein, or their functional equivalents. Such oligodeoxynucleotide sequences can be produced chemically or mechanically, using known techniques.
  • a functional equivalent of an oligonucleotide sequence is one which is 1) a sequence capable of hybridizing to a complementary oligonucleotide to which the sequence (or corresponding sequence portions) of SEQ ID NO: 1, 3, 5, 7, 9 and 11 or fragments thereof hybridizes, or 2) the sequence (or corresponding sequence portion) complementary SEQ ID NO: 1, 3, 5, 7, 9 and 11 and/or 3) a sequence which encodes a product (e.g., a polypeptide or peptide) having the same functional characteristics of the product encoded by the sequence (or corresponding sequence portion) of SEQ ID NO: 1, 3, 5, 7, 9 and 11.
  • a product e.g., a polypeptide or peptide
  • a functional equivalent must meet one or more criteria will depend on its use (e.g., if it is to be used only as an oligoprobe, it need meet only the first or second criteria and if it is to be used to produce a peptide of the present invention, it need only meet the third criterion) .
  • Amb a I and Amb a II proteins have been recombinantly expressed in E ⁇ . coli, purified and shown to have reduced binding to human allergic ragweed pollen IgE on Western blots.
  • Overlapping peptides derived from the Amb a I.l protein and various peptides derived from Amb a 1.3 and Amb a 1.2 were synthesized, and used to identify regions of T cell reactivity within the protein. These regions of T cell reactivity were further defined by modifying selected Amb a I.l peptides and determining T cell reactivity to these peptides.
  • defatted short ragweed pollen (Greer Labs) was extracted in 500 ml .05 M Tris pH 7.95 containing protease inhibitors.
  • the extract was then depigmented by batch absorption with Whatman DE-52 DEAE cellulose (150 g dry weight) in the presence of 0.2 M ⁇ aCl at 4°C. Unbound material was dialysed against .025 M Tris pH 7.95 with protease inhibitors.
  • the depigmented sample was next applied to an 80 ml DEAE cellulose column (Whatman DE-52) equilibrated in .025 M Tris pH 7.95 containing protease inhibitor's. Acidic proteins were eluted with .025 M Tris, 0.2 M NaCl pH 7.95 at 4°C with inhibitors.
  • the acidic DEAE elution sample was fractionated by ammonium sulfate precipitation into 0-45% and 45-59% saturation samples (4°C).
  • the Amb a I-enriched 45-59% pellet was applied at 0.5 ml/min (4°C) to a 500 ml Sephacryl S200 (Pharmacia) column in .05 M ammonium bicarbonate containing inhibitors.
  • Purified Amb a I was recovered in the 38 kD region and dialysed against .04 M Tris pH 8.0. This sample was next applied to an 8 ml Mono Q HR 10/10 (Pharmacia) column in .04 M Tris pH 8.0 at 25°C. Elution was performed with .04 M Tris pH 8.0 containing .08M NaCl and the major peaks were analyzed as discussed below for confirmation and purity of Amb a I.
  • the acidic DEAE elution sample was separated into an Amb a II-enriched fraction by ammonium sulfate precipitation at 0-45% saturation (4°C) .
  • the pellet was applied at 0.5 ml/min (4°C) to a 200 ml Sephadex G75 (Pharmacia) column in .05 M ammonium bicarbonate containing inhibitors.
  • Purified Amb a II was recovered in the 38 kD region and dialysed against .04 M Tris pH 8.0 at 25°C to separate contaminating Amb a I from Amb a II. Elution was performed with .04 M Tris pH 8.0 containing .08M NaCl.
  • nucleotide sequences and deduced amino acid sequences of the Amb a I family members are shown in the sequence listing as SEQ ID NO:l and 2 (Amb a I.l), SEQ ID N0:3 and 4 (Amb a 1.2), SEQ ID NO:5 and 6 (Amb a 1.3), SEQ ID NO:7 and 8 (Amb a 1.4), and SEQ ID NO:9 and 10 (Amb a II).
  • the cDNAs encoding each allergen were cloned in frame with a polylinker encoding six sequential histidines, (CAC)g, that had been inserted into the 5' end of the pTrc99A vector as a NcoI/EcoRI synthetic adapter (Maniatis T., et al. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982) . These cDNA inserts were then cloned in-frame into the appropriate ⁇ Trc99. To further enhance expression, a retroregular stem-loop sequence was placed at the 3' end in the untranslated region (Skoglund, C. M. , et al.
  • the H 6 leader sequence allowed purification using QIAGEN NTA-Agarose (Diagen GmbH, Dusseldorf, FRG), a Ni + chelating support (Hochuli, E. et al., Biotechnology. 6.:1321 (1988)).
  • Recombinant proteins were then obtained by either of the following procedures.
  • the cells were resuspended in lysozyme containing phosphate buffer (0.4 mg/ml) and incubated for 30 minutes on ice. The cell suspension was frozen and quick thawed followed by sonication (Bond, J. G. et al., J. Immunol.. 14.6:3380 (1991)).
  • Insoluble recombinant protein was recovered by a low speed centrifugation and solubulized in 10 ml (per 1 liter growth) of buffer containing 8 M urea, 50 mM Tris, pH 8.0, 2 ⁇ g/ml leupeptin, 2 ⁇ g/ml pepstatin and 1 ⁇ g/ml soybean trypsin inhibitor.
  • the urea solubilized preparation was subjected to a low speed centrifugation and the recombinant proteins in the supernatant isolated by metal ion chromatography (Hochui supra) .
  • the pelleted bacteria were resuspended in 6 M guanidine HCl, 100 mM 2-mercaptoethanol, 100 mM NaP ⁇ 4 , 10 mM Tris pH 8.0.
  • This suspension was subjected to centrifugation at 15,000 X g, and the supernatant removed, adjusted to pH 8.0 with 10 N NaOH, and applied to an NTA agarose column that had been equilibrated in 6 M guanidine HCl, 100 mM NaP ⁇ , 10 "'M Tris pH 8.0. The column was washed in .
  • Recombinant protein (as an Hg fusion) was then eluted in 8 M urea, 100 mM NaOAc, 10 mM Tris pH 4.5 and collected in aliquots whose OD2 8O profile was monitored. The protein peak was dialyzed 3 times into 500 volumes of PBS for human T-cells analysis. Yield ranged from 1-3 ⁇ g of recombinant protein per litre with purity of approximately 55% (as determined by densitometric scanning).
  • Example III IgE Analysis With Purified Recombinant Ragweed Pollen Allergens Both Western blotting and ELISA techniques were used to analyze the binding of IgE to purified recombinant Amb a I and Amb a II proteins. Additionally, ELISA was used for analysis of IgE reactivity to peptides derived from the Amb a 1.1 protein.
  • the antigens were loaded on the gels as follows: lane 1 SPE (Soluble Pollen Extract), 15 ⁇ g/lane; lane 2 rAmb a I.l (recombinant Amb a I.l), 3 ⁇ g/lane; lane 3 rAmb a 1.2, 4 ⁇ g/lane; lane 4 rAmb a 1.3, 3 ⁇ g/lane; lane 5 rAmb a 1.4, 3 ⁇ g/lane; and lane- 6 rAmb a II.1, 4 ⁇ g/lane.
  • the blots were rinsed in blot solution (25 mM Tris-HCl, pH 7.5, 0.17 M NaCl, and 0.05% Tween 20) and stained for 1 hour with 0.1% India ink. All subsequent incubations with antibodies and washes were performed in blot solution at room temperature. The first antibody incubations were performed overnight then rinsed and incubated with the appropriate biotinylated second antibody (Kirkegaard Perry Laboratories, Gaithersburg, MD) . The final incubation was performed using 125-1 streptavidin (1 ⁇ Ci/25 ml blot solution) for 1 hour followed by removal of unbound labeled material and autoradiography at -80°C with an intensifying screen.
  • blot solution 25 mM Tris-HCl, pH 7.5, 0.17 M NaCl, and 0.05% Tween 20
  • All subsequent incubations with antibodies and washes were performed in blot solution at room temperature. The first antibody incubations were performed overnight then rinsed and
  • Fig. 1 shows the Western blot IgE binding pattern of two ragweed allergic patient plasma samples (#475 and #143). These patterns are representative of the typical IgE reactivity to these proteins on a Western blot. Both patients show binding to the Amb a I.l and Amb a 1.3 gene products in the soluble pollen extract (lane 1, Fig. 1). The results demonstrate clear IgE binding reactivity in these patients to Amb a I.l, Amb a 1.3, Amb a 1.4. In contrast, Amb a 1.2 and Amb a II.1 showed markedly reduced IgE binding.
  • Fig. 2 shows the results of this analysis performed according to the following method.
  • Corning assay plates (#25882-96) were coated with each antigen listed in Fig. 2 at the following concentrations: Soluble Pollen Extract (SPE) 15 ⁇ g/ml; rAmb a I.l, 5 ⁇ g/ml; rAmb a 1.2, 20 ⁇ g/ml; rAmb a 1.3, 5 ⁇ g/ml; rAmb a 1.4, 15 ⁇ g/ml; and rAmb a II, 20 ⁇ g/ml.
  • SPE Soluble Pollen Extract
  • FIG. 3 Another ELISA assay was performed using a pool of human allergic sera. This assay demonstrates that biochemically purified (native) Amb a I and Amb a II proteins bind significantly more IgE than the respective recombinant proteins (rAmb a I.l and rAmb a II). (The control in this experiment was plates coated without antigen and PBS) .
  • Example IV Tolerization of Mice with Recombinant Amb a I Proteins Balb/c mice (H-2 d) were immunized in the hind foot pads and at the base of the tail with an emulsion of Complete Freunds Adjuvant (CFA) and 50 ⁇ g/mouse Amb a I.l. Seven days later, the popliteal lymph nodes, superficial inguinal lymph nodes, and the periaortic lymph nodes were harvested and cultured (1 x 10 5 lymph node cells + 2 x 10 5 irradiated spleen feeders) with various challenge antigens in vitro.
  • CFA Complete Freunds Adjuvant
  • the in vitro antigens consisted of various doses of Amb a I.l, Amb a 1.2, Amb a 1.3, Amb a 1.4, Amb a II, and a media control. Cultures were incubated for 3 days at 37°C in a CO 2 incubator. On day 3, each culture was pulsed with l ⁇ Ci 3 H thymidine and on day 4 the cultures were harvested and proliferation was monitored by incorporation of 3 H into DNA.
  • mice that were immunized with 50 ⁇ g Amb a I.l + CFA have a good response to Amb a I.l, Amb a 1.3, and Amb a 1.4.
  • the response to Amb a 1.2 and Amb a II is also good but less than other antigens. It appears as though Amb a I.l is very immunogenic in Balb/c mice and results in a response to each Amb a family member. When mice were immunized with PBS + CFA, there was no significant response to any of the Amb a family members (Fig. 4B) .
  • mice were tolerized with Amb a I.l and pollen extract and then challenged with Amb a I.l or pollen extract.
  • the outline of this experiment #5 is shown below: Day 1: Group (1): 6 Balb/c mice tolerized with
  • Group (2) 6 Balb/c mice tolerized with
  • Group (3) 6 Balb/c mice exposed to PBS +
  • the animals were sacrificed by cervical dislocation on day 23 and the popliteal lymph nodes, superficial inguinal lymph nodes, and the periaortic lymph nodes were removed and placed in rinsing buffer (cold RPMI 1640 containing 1% FCS) .
  • the nodes were rinsed with rinsing buffer and forced through a fine stainless steel mesh, using a glass pestal to suspend them in rinsing buffer.
  • the suspended cells were rinsed two times by centrifugation at 1000 rpm for 10 minutes and resuspended in rinsing buffer. An aliquot from each sample was taken in order to do a cell count.
  • the cells (4 x 10 6 /ml) were incubated in culture media (RPMI 1640 media containing 10% FCS, 2mM L-glutamine, 50U/ml penicillin, 50 ⁇ g/ml streptomycin and 5 x 10 ⁇ 5 M 2-mercaptoethanol) and test antigens at various concentrations.
  • culture media RPMI 1640 media containing 10% FCS, 2mM L-glutamine, 50U/ml penicillin, 50 ⁇ g/ml streptomycin and 5 x 10 ⁇ 5 M 2-mercaptoethanol
  • the triplicate 0.1 ml cultures (U-bottom 96 well plates (Costar)) were incubated at 37°C and at 5% CO2. After 24 hours, 50 ⁇ l of media from each well was placed in separate flat bottom 96 well plates (Costar) and frozen overnight at -20°C to eliminate carryover of live cells.
  • CTLL3 in log phase growth were rinsed 3 times by centrifugation at 1000 rpm for 10 minutes.
  • CTLL3's were added to the warmed culture supernatants (5 x 10 3 cells/well) and the IL-2 assay was incubated at 37°C and 5% C0 2 .
  • 1 ⁇ Ci/well 3 H thymidine was added in 50 ⁇ l/well and the CTLL3 cells were incubated for an additional 4-6 hours.
  • the plates were harvested on a Tom Tek 96 well cell harvester. The H incorporation in each well was counted by a Betaplate Model 1205 scintillation counter. Background counts were not subtracted.
  • Fig. 5 shows the lymph node responses to Amb .a I.l, Amb a 1.2, Amb a 1.3, Amb a 1.4, and Amb a II in the mice that were tolerized with Amb a I.l or Phosphate Buffered Saline (PBS) and challenged with Amb a I.l.
  • Fig. 5A shows that the mice that were tolerized with Amb a I.l have a lower response to Amb a. I.l than the mice that were tolerized with PBS. The same appears to be true in the response to Amb a 1.2, Amb a 1.3, and Amb a 1.4 (Figs. 5B, 5C, 5D) .
  • Figs. 5B, 5C, 5D the lymph node responses to Amb .a I.l, Amb a 1.2, Amb a 1.3, Amb a 1.4
  • FIGs. 6A-6F show the lymph node responses to the various proteins in the mice that were exposed to pollen extract or PBS and challenged with pollen extract. Table 1 summarizes the results of these experiments.
  • Amb a I.l overlapping peptides as shown in Fig. 7 were synthesized using standard Fmoc/tBoc synthetic chemistry and purified by dialysis or Reverse Phase HPLC.
  • various peptides derived from Amb a 1.2 and Amb a 1.3 were synthesized.
  • the amino acid residues of the synthesized peptides are in brackets by the peptide name and the amino acid sequence (in single letter code) is next to the peptide name.
  • the peptide names are consistent throughout the Figures.
  • the relationship of the Amb a I family members at the level of T cell cross-reactivity as determined in Example VIII was considered.
  • the Amb a I protein allergens share a high degree of cross-reactivity.
  • Amb a I.l and Amb a II were found to have 55.2% cross-reactivity.
  • the amino acid sequences of the Amb a I family members and Amb a II were examined to identify conserved and variable regions. It was expected that conserved regions within the Amb a I family members and Amb a II would contain "shared" T cell epitopes.
  • PBMC Peripheral blood mononuclear cells
  • LSM lymphocyte separation medium
  • Viable cells were purified by LSM centrifugation and cultured in complete medium supplemented with 5 units recombinant human IL-2/ml and 5 units recombinant human IL-4/ml for up to three weeks until the cells no longer responded to lymphokines and were considered "rested”. The ability of the T cells to proliferate to Amb a I.l, Amb a 1.2 and " Amb a 1.3 sequence-derived synthetic peptides was then assessed.
  • 2 x 10 4 rested cells were restimulated in the presence of 2 x 10 4' autologous Epstein-Barr virus (EBV)-transformed B cells (gamma-irradiated with 25,000 RADS) or 5 x 10 4 autologous PBMC (3,500 RADS) with various concentrations of Amb a I.l synthetic peptides in a volume of 200 ⁇ l complete medium in duplicate or triplicate wells in 96-well round bottom plates for 3 days. Each well then received 1 ⁇ Ci tritiated thymidine for 16-20 hours. The counts incorporated were collected onto glass fiber filter mats and processed for liquid scintillation counting. Table II shows the results of a representative assay.
  • EBV Epstein-Barr virus
  • the maximum response in a titration of each peptide is expressed as the S.I. or stimulation index.
  • the S.I. is the CPM incorporated by cells in response to peptide divided by the CPM incorporated by cells in medium only.
  • An S.I. value greater than the background level is considered "positive" and indicates that the peptide contains a T cell epitope.
  • only individual S.I. values above 2.0 were used in calculating mean stimulation indices for each peptide for the group of patients tested.
  • the results shown in Table II demonstrate that this patient (#466) responds very well to peptides RAE 7.D, RAE 69.1, RAE 64.1, and RAE 29.1. This indicates that these peptides contain Amb a I.l T cell epitopes recognized by T cells from this particular allergic patient.
  • the ranks for each peptide were then summed in the 39 patients to determine the cumulative rank for the peptide.
  • the number above each bar is the mean S.I. of the positive responses (S.I. of 2.0 or greater) from the group of patients to that peptide.
  • the positivity index (P.I) is the positivity index (P.I).
  • the P.I. for each peptide is determined by multiplying the mean S.I. by the percent of patients who responded to that peptide. The P.I. therefore represents both the strength of the response (S.I.) and the frequency of a response to a peptide in the group of patients tested.
  • peptide RAE 69.1 had the highest cumulative rank so it was the best peptide response in the overall population of 39 even through it did not have the highest mean S.I.
  • RAE 70.1 had the highest mean S.I but not the best cumulative rank or P.I.
  • the response to RAE 70.1 was strong when it occurred but it did not occur as frequently in the population as the response to other peptides.
  • the peptide with the highest P.I., RAE 29.1 also had a strong S.I. and the second highest cumulative rank. The response to this peptide was therefore generally strong and relatively frequent in this population.
  • Example VII T Cell Epitope Fine Map Studies with Amb a I.l
  • Amb a I.l Based on the above analysis 4 major areas of T cell reactivity within Amb a I.l were identified. (Regions 1, 2, 3 and 4) . All 39 patients responded to Amb a I.l and a peptide from at least one of these regions: Region 1, amino acids residues 48-107; Region 2, amino acid residues 171-216; Region 3, amino acid residues 278-322; and Region 4, amino acid residues 331-377.
  • Amb a I.l peptides were selected and modified by addition or deletion of amino acid residues at either the 5' or 3" end of the peptide. This set of peptides is shown in Fig. 9.
  • T cell studies similar to those of Example VI were performed using these selected peptides to more precisely define the major areas of T cell reactivity within Regions 1-4 of the Amb a I.l protein.
  • PBMC from a single ragweed-allergic patient were isolated as described in Example VI and were stimulated with 20 ⁇ g/ml of recombinant Amb a I.l as described above.
  • the results of proliferation assays with this one patient to selected peptides using irradiated (24,000 RADS) autologous EBV B cells as antigen presenting cells is shown in Table III. The data indicates that T cells from this patient respond well to RAE 7.D, RAE 70.1, RAE 40.1-4, and RAE 28.1-2. TABLE III
  • Fig. 10 indicates that the major area of T cell reactivity within Region 1 of the Amb a I.l protein is represented by peptides RAE 6.D, RAE 7.D, RAE 40.1, RAE 40.1-4, and RAE 40.1-5.
  • a preferred area of major T cell reactivity within Region 1 comprises amino acid residues 57-101.
  • Fig. 11 indicates that there is a broad area of weak T cell reactivity in Region 2 of the Amb a I.l protein relative to Region 1.
  • a preferred area of major T cell reactivity within Region 2 thus comprises amino acid residues 182-216.
  • Fig. 12 shows that the most frequent and dominant response within Region 3 of the Amb a 1.3 protein is to peptide RAE 64.1.
  • T cell reactivity is represented by peptide RAE 66.1.
  • a preferred area of major T cell reactivity within Region 3 comprises amino acid residues 280-322.
  • Fig. 13 indicates that the major area of T cell reactivity in Region 4 is represented by peptides RAE 28.1-2, RAE 28.1-1, and RAE 28.1. From this analysis, a preferred area of major T cell reactivity within Region 4 comprises amino acid residues 342-377.
  • selected peptides from Regions 1-4 were further modified by addition or deletion of amino acid residues as described above. These selected modified peptides are shown in Fig. 14.
  • PBMC peripheral blood mononuclear cells
  • 2 x 10 4 rested cells were restimulated in the presence of an equal number of autologous EBV-transformed B cells (irradiated with 25,000 RADS) with various concentrations (0-100 ⁇ g/ml) of recombinant Amb a I.l, 1.2, 1.3, 1.4, Amb a II, or ragweed pollen extract in a volume of 200 ⁇ l complete medium in duplicate or triplicate wells in 96-well round bottom plates for 3 days. Each well then received 1 ⁇ Ci tritiated thymidine for 16-20 hours. The counts incorporated were assessed and analyzed as described in Example VI.
  • Table IV shows the S.I., P.I., percent of cultures positive for the assay antigen, and number of cultures analyzed. For these assays an individual S.I. greater or equal to 2.0 was used in calculating the mean S.I. Amb a I.l stimulated cells respond less well and less frequently to the least homologous family members 1.3 and 1.2. However, this level of cross-reactivity, 68.8% and 60% respectively, is still considered high. The lowest level of Amb a I.l stimulated T cell cross-reactivity is noted to the least homologous allergen, Amb a II. In addition, Amb a I.l reactive T cells are found at a high percentage from ragweed pollen extract stimulated cultures, again demonstrating the importance of the Amb a I.l allergen.
  • PBMC from ragweed allergic patients were stimulated with 20 ⁇ g/ml recombinant Amb a I.l protein as described in Example VI with the addition of cultures of PBMC which were stimulated with 20 ⁇ g/ml recombinant Amb a 1.3 protein.
  • Assays were performed as described in Example VI except the homologous Amb a 1.3 peptides were also tested at various doses. In these experiments an individual S.I of 2.0 or greater was used in calculating the mean S.I. Fig.
  • FIG. 19 shows the results from a set of 9 matched patients stimulated with either recombinant Amb a I.l protein or recombinant Amb a 1.3 protein and tested on the set of Amb a I.l peptides described above.
  • Each bar represents the P.I.
  • the dark bar represents cells stimulated with recombinant Amb a I.l protein and tested with Amb a I.l peptides
  • the stippled bar represents cells stimulated with recombinant Amb a 1.3 protein and tested with Amb a I.l peptides.
  • Amb a I.l specific T cell reactivity selected peptides from Figure 14 were analyzed.
  • Amb a I.l specific T cells lines were derived from 28 ragweed allergic patients as described in Example VI. These lines were assessed for their ability to proliferate in response to the peptide in the presence of autologous EBV transformed antigen presenting cells by the uptake of tritiated .thymidine as described previously.
  • Several lysine substituted peptides derived from the peptide RAE 70.1 sequence were designed to increase the solubility of the peptide from Region 2.
  • These peptides shown in Figure 22 were tested against non-substituted controls to determine if the modification resulted in a change in T cell reactivity.
  • truncations of peptide AMB 4-6.1 amino acid residues 347-377) were tested to further refine the relative T cell reactivity in that region.
  • Figure 22 shows the responses of the 28 T cell lines to these peptides as analyzed by the positivity index, the mean stimulation index and the percent of positive responses.
  • the positivity index as defined previously, is the mean stimulation index multiplied by the percent of patients responding to a peptide. Responses to peptides were considered positive if they were greater or equal to 2 fold over background.
  • Figure 22 demonstrates that certain lysine substituted peptides in the 182-216 sequence resulted in greater T cell responses, indicating that not all substitutions are recognized equally by a given T cell line.
  • the T cell responses to the lysine modified peptides having a substitution of cysteine at position 212 with serine reflect the responses of T cell lines tested with peptides without the lysine substitutions.
  • the decrease in response to AMB 2-10.1, with a substitution of leucine for cysteine at 212 reflects the decrease in the percentage of patients responding to this peptide relative to peptides AMB 2-9.1 and AMB 2-11.1 which contain serine and glutamic acid substitutions, respectively, at position 212.
  • AMB 4-9.1EP glutamic acid
  • AMB 4-9.INP asparagine
  • AMB 4-9.1AP alanine
  • AMB 4-9.ISP serine
  • AMB 4-9.1QP glutamine
  • FIG. 23 shows the ranked sum of the strongest three peptide responses in the 28 T cell lines. The ranked sum was determined as described previously with the strongest response to a peptide given a value of 3, the second strongest a 2, and the third strongest a value of 1. The values from all 28 lines were then added to obtain the ranked sum.
  • Figure 23 indicates that the modified peptide AMB 4-9.IDA elicits T cell responses similar to those of the native sequence AMB 4-9.1. In contrast, other substitutions, while eliciting strong responses do not rank as highly in this analysis.
  • peptides were selected for further study (AMB 1-2.1, AMB 2-6.1, AMB 2-9.1, AMB 3-5.1 and AMB 4-9.1).
  • An additional peptide, RA-02.1 (SEQ ID NO:150) was also synthesized and tested to confirm that the serine substitution at position 212 was recognized by Amb a I.l specific T cell lines.
  • the T cell reactivity of these peptides in 32 different Amb . ⁇ . I.l specific T cell lines was determined as described previously.
  • Figure 24 demonstrates the relative positivity indices, percent of positive responses and mean stimulation indices of these six peptides compared to the overall response to Amb a I.l. This figure shows that peptide AMB 4-9.1 elicits the strongest response in a high percentage of patients.
  • Toxicity defined as proliferation, as assessed by incorporation of tritiated thymidine, which is less than half the proliferation of media control of an Amb a I.l stimulated T cell line plus APC.
  • RAE 70.1 SEQ ID NO:44
  • peptide RAE 70.1 was divided into two fragments and modified to increase solubility and to further define the residues necessary for T cell reactivity.
  • a fragment of RAE 70.1 amino acid residues 194-216 was modified by substitution or addition of amino acids which would increase the hydrophilicity and decrease the pi of the peptide to thereby increase solubility.
  • Peptides Amb 2-18.1 (SEQ ID NO:126), Amb2-19.1 (SEQ ID NO:127), Amb2-20.1 (SEQ ID NO:128) and Amb2-21.1 (SEQ ID NO:129) correspond to different lengths of the original peptide which were synthesized (including the serine substitution at position 212) and analyzed to determine solubility. It was found that peptide Amb2-19.1 (residues 200-217) was most soluble. Thus, substitutions and/or amino acid additions to this peptide were made in order to further increase the solubility while maintaining T cell reactivity.
  • Figures 27 and 28 show representative examples of proliferation of two individual Amb a I.l specific T cell lines to peptides selected from those shown in Figure 25. Assays were performed as described previously. Both Figure 27 and Figure 28 indicate a hierarchy of responses to these peptides. Patient 119 shown in Figure 27, has a hierarchy of response from strongest to weakest as follows:
  • Peptides AMB2-34.1, AMB2-35.1, and AMB 2-9.1 did not elicit significant T cell proliferation in this patient.
  • Patient 1199 shown in Figure 28 demonstrated strong responses to AMB 2-26.1>AMB 2-22.1>AMB 2-33.1. T cells from this patient showed less than 2 fold over background responses to all other* peptides. These responses are not significantly different from the media control of the T cell line plus autologous EBV antigen presenting cells.
  • a T cell clone was generated by limiting dilution from an Amb a I.l specific T cell line stimulated with AMB 2-10.1. Briefly, an Amb a I.l specific T cell line from patient 776 was shown to respond to AMB 2-10.1 in a proliferation assay as described previously.
  • Amb a I.l specific T cells were plated at 0.3 cells/well in a V-bottom 96 well plate with 20,000 irradiated autologous EBV transformed antigen presenting cells, AMB 2-10.1 at 40 ⁇ g/ml, leukoagglutin at 1 mg/ml, and recombinant human IL-2 and IL-4 at 10 units/ml in a total volume of lOO ⁇ l/well.
  • Plating the T cells at 0.3 cells/well insures not more than 1 T cell/well can potentially proliferate to the peptide with the progeny of that T cell representing a clonal population.
  • IL-2 and IL-4 were recombinant human IL-2 and IL-4 to expand peptide-specific T cells.
  • This addition of IL-2 and IL-4 was repeated again every three days for the duration of the culture period. Twelve days after the initiation of culture, T cells in the wells were restimulated with 20,000 irradiated EBV antigen presenting cells and 40 ⁇ g/ml AMB 2-10.1. This was repeated again 20 days after the initial stimulation. T cells from wells which showed signs of growth were separated from cell debris by density centrifugation as described previously in the generation of T cell lines. The T cell clone was then expanded with additional IL-2 and IL-4 at 10 units/ml until there were significant numbers to assay for proliferation.
  • the objective of the histamine release analysis was to compare the effects of Amb a I.l or Amb a I.l-derived peptides in an vitro allergic response system.
  • the release of histamine via IgE recognition and IgE receptor crosslinking on viable cells directly assays the allergic potential of a protein antigen.
  • the histamine release assay used for these studies is based on the detection of an acylated derivative of histamine using a specific monoclonal antibody (Morel, A.M. and Delaage, M.A. (1988) J. Allergy Clin. Immunol. 82:646-654).
  • the assay was performed in two steps: 1) the release of histamine from basophils present in heparinized whole blood in the presence of different concentrations of protein or peptide; and 2) the assay of histamine present in the supernatants of the release reactions following cell removal by centrifugation.
  • the reagents for this second step are available commercially as a competitive radioimmunoassay from AMAC Inc. (Westbrook, ME) .
  • test protein Amb a I.l and peptides AMB 1-2.1, AMB 2-9.1, AMB 4-9.1, and AMB 3-5.1 were each diluted to 2X the final release concentration in PACM buffer (PIPES 25mM, ⁇ aCl HOmM, KC1 5.0 mM, human serum albumin 0.003% (w/v), CaCl2 5mM, MgCl2 2mM, pH7.3) and 0.2 ml of each dilution was added to a 1.5 ml polypropylene tube. A 0.2ml aliquot of blood was then added to each tube and the release reactions started by inversion of the tubes.
  • PACM buffer PPES 25mM, ⁇ aCl HOmM, KC1 5.0 mM, human serum albumin 0.003% (w/v), CaCl2 5mM, MgCl2 2mM, pH7.3
  • a negative control of 0.2 ml blood incubated with 0.2 ml PACM buffer was also included. The release reactions were performed for 30 minutes at 37°C. The tubes were then centrifuged in a microfuge at 1500 RPM for 3 minutes and the supernatants were carefully removed and analyzed or stored at -20°C for later analysis. To analyze the total histamine released, 0.1 ml blood was diluted with 0.9 ml PACM buffer and boiled 3 minutes. This tube was then centrifuged 2 minutes at 12,000 RPM and the supernatant was removed and save for analysis.
  • a 50 ⁇ l aliquot of each release supernatant was mixed with 150 ⁇ l of histamine release buffer (supplied with the kit from AMAC) .
  • the diluted supernatant 100 ⁇ l was added to a kit tube containing an acylation reagent.
  • a 50 ⁇ l aliquot of acylation buffer was then immediately added and the tube mixed by vortexing.
  • the acylation reactions were incubated at least 30 minutes at room temperature.
  • a set of histamine standards supplied with the kit were acylated at the same time. 50 ⁇ l of each acylation reaction was then placed in a tube coated with a monoclonal antibody which specifically recognizes the acylated form of histamine.
  • a standard curve was generated from the histamine standard counts and graphed on a semi-log plot. Since this is a competitive assay (the 125 -labelled tracer competes with acylated histamine in the samples for binding to the antibody-coated tubes), the lower the number of radioactive counts measured, the greater the amount of histamine in the sample. The amount of histamine in each sample data point was extrapolated from the standard curve using a computer statistical program (StatView for the Macintosh). The assay is sensitive to 0.2 nM histamine.
  • FIG. 30 shows the representative results from 1 of the patients (#1273).
  • the graph shows the concentration of each antigen in ⁇ g/ml versus the percent of total histamine released. The results are presented as the percent of the total histamine released for that patient, since patients vary greatly in their overall releasable histamine levels. This variability is likely to result from variation in the number of basophils per ml between patients and the histamine content of each basophil.
  • Amb a I.l at all the concentrations tested, yields a high level of histamine release in this patient.
  • NAME Mandragouras, Amy E.
  • GCT GGT GTA CTC TCA TGC CAA CCC GGA GCA CCT TGC TAAGCACCCG 11
  • ATC AAG AAA AAT GTC TTA GCG AGG ACT GGT ACT GGC AAC GCA GAG TCG 10 He Lys Lys Asn Val Leu Ala Arg Thr Gly Thr Gly Asn Ala Glu Ser 325 330 335
  • GGC ATG ATG CAA GCT GAA CCG GGA GAT ATG GTT CCA CAA CTC ACC ATG 1152 Gly Met Met Gin Ala Glu Pro Gly Asp Met Val Pro Gin Leu Thr Met 370 375 380
  • AAG GAG AAT GCT GCT CTG GAG TTT GGA AAA GTA ATA GAA AAA AAG CAG 144 Lys Glu Asn Ala Ala Leu Glu Phe Gly Lys Val He Glu Lys Lys Gin 35 40 45

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP93911584A 1992-04-09 1993-04-06 T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA) Withdrawn EP0636180A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96202492A EP0770681A3 (en) 1992-04-09 1993-04-06 T cell epitopes of the major allergens from ambrosia artemisiifolia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86667992A 1992-04-09 1992-04-09
US866679 1992-04-09
PCT/US1993/003156 WO1993021321A2 (en) 1992-04-09 1993-04-06 T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP96202492A Division EP0770681A3 (en) 1992-04-09 1993-04-06 T cell epitopes of the major allergens from ambrosia artemisiifolia

Publications (1)

Publication Number Publication Date
EP0636180A1 true EP0636180A1 (en) 1995-02-01

Family

ID=25348157

Family Applications (2)

Application Number Title Priority Date Filing Date
EP96202492A Withdrawn EP0770681A3 (en) 1992-04-09 1993-04-06 T cell epitopes of the major allergens from ambrosia artemisiifolia
EP93911584A Withdrawn EP0636180A1 (en) 1992-04-09 1993-04-06 T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP96202492A Withdrawn EP0770681A3 (en) 1992-04-09 1993-04-06 T cell epitopes of the major allergens from ambrosia artemisiifolia

Country Status (12)

Country Link
EP (2) EP0770681A3 (no)
JP (1) JPH07507924A (no)
KR (1) KR950700991A (no)
AU (1) AU685392B2 (no)
CA (1) CA2117779A1 (no)
FI (1) FI944697A (no)
IL (1) IL105352A0 (no)
MX (1) MX9302024A (no)
NO (1) NO943811L (no)
NZ (1) NZ252013A (no)
WO (1) WO1993021321A2 (no)
ZA (1) ZA932530B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759234B1 (en) 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
AU748104B2 (en) * 1994-09-02 2002-05-30 Merck Patent Gmbh Peptide compositions capable of down regulating an antigen specific immune response
CZ63297A3 (en) * 1994-09-02 1997-08-13 Immulogic Pharma Corp Peptide preparations capable of attenuating antigen specific immune response
WO1996013589A1 (en) * 1994-10-27 1996-05-09 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from ambrosia artemisiifolia
CA2247009C (en) 1996-03-21 2009-08-04 Imperial College Of Science, Technology And Medicine Cryptic peptides and method for their identification
AU2001252246A1 (en) * 2000-04-05 2001-10-23 Syngenta Participations Ag Therapeutically active proteins in plants
EP1958645A1 (en) * 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
ES2378870T5 (es) * 2008-08-15 2016-02-03 Circassia Limited Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía
US8821887B2 (en) 2008-08-15 2014-09-02 Circassia Limited T-cell antigen peptide from allergen for stimulation of IL-10 production
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
CA2839832C (en) * 2011-06-27 2018-08-28 Anergis S.A. Contiguous overlapping peptides for treatment of ragweed pollen allergy
WO2017179025A1 (en) * 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463059B1 (en) * 1989-03-17 1998-12-30 Immulogic Pharmaceutical Corporation Allergenic proteins from ragweed and uses therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9321321A2 *

Also Published As

Publication number Publication date
KR950700991A (ko) 1995-02-20
FI944697A (fi) 1994-12-07
WO1993021321A2 (en) 1993-10-28
AU4046293A (en) 1993-11-18
WO1993021321A3 (en) 1994-02-03
CA2117779A1 (en) 1993-10-28
NZ252013A (en) 1996-08-27
ZA932530B (en) 1993-10-28
NO943811L (no) 1994-12-06
MX9302024A (es) 1994-07-29
JPH07507924A (ja) 1995-09-07
EP0770681A3 (en) 1997-06-04
EP0770681A2 (en) 1997-05-02
IL105352A0 (en) 1993-08-18
NO943811D0 (no) 1994-10-07
AU685392B2 (en) 1998-01-22
FI944697A0 (fi) 1994-10-07

Similar Documents

Publication Publication Date Title
JP2009005709A (ja) ダーマトファゴイデス（家ほこりダニ）からの主要なアレルゲンのｔ細胞エピトープの製造方法
AU690900B2 (en) Allergenic protein and peptides from house dust mite and uses therefor
US8287875B2 (en) Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor
EP0636180A1 (en) T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA)
EP0688338A1 (en) T cell epitopes of ryegrass pollen allergen
US5710126A (en) T cell epitopes of ryegrass pollen allergen
EP0669983A1 (en) Allergenic proteins and peptides from japanese cedar pollen
AU7559794A (en) T cell epitopes of ryegrass pollen allergen
WO1996013589A1 (en) T cell epitopes of the major allergens from ambrosia artemisiifolia
US5698204A (en) Recombinant allergenic proteins from ragweed pollen
US7112333B1 (en) T cell epitopes of ryegrass pollen allergen
EP0694067B1 (en) T cell epitopes of the major allergens from dermatophagoides (house dust mite)
KR100733887B1 (ko) DerpⅢ단백질알레르겐을암호화하는분리된핵산

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19951129

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19981013